• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Cytokines in pancreatic carcinoma

Correlation with phenotypic characteristics and prognosis

  1. Behnam Ebrahimi M.D.1,
  2. Susan L. Tucker Ph.D.2,
  3. Donghui Li Ph.D.1,
  4. James L. Abbruzzese M.D.1,
  5. Razelle Kurzrock M.D.1,3,†,*

Article first published online: 3 NOV 2004

DOI: 10.1002/cncr.20672

Issue

Cancer

Cancer

Volume 101, Issue 12, pages 2727–2736, 15 December 2004

Additional Information

How to Cite

Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L. and Kurzrock, R. (2004), Cytokines in pancreatic carcinoma. Cancer, 101: 2727–2736. doi: 10.1002/cncr.20672

Author Information

  1. 1

    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Biomathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Phase I Program, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 745-2374

*Phase I Program, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Box 422, 1515 Holcombe Boulevard, Houston, TX 77030

  1. †

    Fax: (713) 745-2374

Publication History

  1. Issue published online: 1 DEC 2004
  2. Article first published online: 3 NOV 2004
  3. Manuscript Accepted: 19 AUG 2004
  4. Manuscript Revised: 19 JUL 2004
  5. Manuscript Received: 14 MAY 2004

Funded by

  • Morton and Angela Topfer Fund
  • Pancreatic Cancer Specialized Program of Research Excellence in Pancreatic Cancer. Grant Number: 1P20 CA101936-01

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (159K)

REFERENCES

  • 1
    Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol. 2003; 30(4 Suppl 11 ): 3–10.
  • 2
    Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97: 256–263.
  • 3
    Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma. 1997; 26: 251–259.
  • 4
    Gause A, Scholz R, Klein S, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol. 1991; 9: 307–313.
    Direct Link:
  • 5
    Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993; 53: 2118–2122.
  • 6
    Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med. 1997; 102: 21–28.
  • 7
    Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphomas. Leuk Lymphoma. 1998; 30: 563–571.
  • 8
    Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal carcinoma. Cancer Res. 1992; 50: 3317–3322.
  • 9
    Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001; 19: 239–247.
  • 10
    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5: 119–127.
  • 11
    Xie K. Survey: interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12: 375–391.
  • 12
    Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995; 13: 575–582.
  • 13
    Preti AH, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large cell lymphomas. Ann Intern Med. 1997; 127: 186–194.
  • 14
    Blay JY, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J. Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas. Blood. 1995; 86: 4702–4704.
  • 15
    Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphomas: a prognostic factor. Blood. 1993; 82: 2169–2174.
  • 16
    Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991; 78: 1476–1484.
  • 17
    Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994; 84: 3142–3147.
  • 18
    Barnes PJ, Karin M. Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336: 1066–1071.
  • 19
    Daftarian PM, Kumar A, Kryworuchko M, Diaz-Mitoma F. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J Immunol. 1996; 157: 12–20.
  • 20
    Blanchard JA II, Barve S, Joshi-Barve S, Talwalker R, Gates LK Jr. Cytokine production by CAPAN-1 and CAPAN-2 cell lines. Dig Dis Sci. 2000; 45: 927–932.
  • 21
    Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995; 86: 1243–1254.
  • 22
    Freeman GJ, Freedman AS, Rabinowe SN, et al. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989; 83: 1512–1518.
  • 23
    Seymour JF, Kurzrock R. Interleukin-6: biologic properties and role in lymphoproliferative disorders. In: FreireichEJ, KantarjianHM, editors. Molecular genetics and therapy of leukemia. Boston: Kluwer Academic Publishers, 1996: 204–217.
  • 24
    Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995; 85: 863–872.
  • 25
    Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman's disease. Blood. 1989; 74: 1360–1367.
  • 26
    Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992; 11: 587–592.
  • 27
    Scala G, Quinto I, Ruocco MR, et al. Expression of an exogenous interleukin 6 in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med. 1990; 172: 61–68.
  • 28
    Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest. 1993; 91: 2806–2814.
  • 29
    Yee C, Blandi A, Wang XH, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989; 74: 798–804.
  • 30
    Twillie DA, Eisenberger MA, Carducce MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995; 45: 542–549.
  • 31
    Berek JS, Chung C, Kaidi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991; 164: 1038–1043.
  • 32
    Ludwig H, Nachbaur DM, Fritz E, et al. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991; 77: 2794–2795.
  • 33
    Nachbaur DM, Herold M, Maneschg A, et al. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991; 62: 54–58.
  • 34
    Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003; 83: 222–226.
    Direct Link:
  • 35
    Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998; 28: 12–15.
  • 36
    Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994; 219: 325–331.
  • 37
    O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol. 1999; 15: 823–827.
  • 38
    Opp M, Obal F, Cady AB, et al. Interleukin-6 is pyrogenic but not somnogenic. Physiol Behav. 1989; 45: 1069–1072.
  • 39
    Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene causes hypercalcemia as well as cachexia, leukocytosis, and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991; 128: 2657–2659.
  • 40
    Strassman G, Fong M, Kenney JS, et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992; 89: 1681–1684.
  • 41
    Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993; 11: 499–506.
  • 42
    Mackiewicz A, Schooltink H, Heinrich PC, et al. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992; 149: 2021–2027.
  • 43
    Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by the TH1 clones. J Exp Med. 1989; 170: 2081–2095.
  • 44
    Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphomas constitutevely secrete large quantities of interleukin-10. Blood. 1992; 80: 1289–1298.
  • 45
    O'Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B-cells: lymphomas and normal B-cells produce interleukin 10. Int Immunol. 1990; 2: 821–832.
  • 46
    O'Garra A, Chang R, Hastings R, Hastings R, Haughton G, Howard M. Ly-l B (B-1) cells are the main source of B-cell derived interleukin 10. Eur J Immunol. 1992; 22: 711–717.
    Direct Link:
  • 47
    Go NF, Castle BE, Barrett R, et al. Interleukin 10, a novel B-cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med. 1990; 172: 1625–1631.
  • 48
    Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992; 98: 1890–1893.
  • 49
    Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med. 1991; 173: 507–510.
  • 50
    Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995; 85: 2516–2520.
  • 51
    Galizia G, Lieto E, DeVita F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res. 2002; 22: 473–482.
  • 52
    Hatanaka H, Abe Y, Kamiya T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol. 2000; 11: 815–819.
  • 53
    Arend WP. The balance between IL-1 and IL1-Ra in disease. Cytokine Growth Factor Rev. 2002; 13: 323–340.
  • 54
    Estrov Z, Kurzrock R, Estey E, et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992; 79: 1938–1945.
View Full Article (HTML) Get PDF (159K)